Загрузка...
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
IMPORTANCE: The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. OBJECTIVE: To evaluate the efficacy and safety of inotuzumab ozogamicin pl...
Сохранить в:
| Опубликовано в: : | JAMA Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Medical Association
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5838597/ https://ncbi.nlm.nih.gov/pubmed/28859185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2380 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|